Vaccines & Biodefense

In the U.S., the recommended immunization series prevents approximately 33,000 deaths each year. Advancements in biotechnology have made it possible to produce vaccines that cannot transmit a virus or bacterium. This method has helped create more than 20 new vaccines against infectious agents, improved existing vaccines, and increased the amount of vaccine that can be produced.

Partnering with the Department of Defense to Protect the Warfighter: Investments in National Health Security

Webinar recorded on June 30, 2022, and moderated by Phyllis Arthur, Vice President, Infectious Disease and Emerging Science Policy, BIO.  Webinar slides are available at this link.

The US Government invests in biomedical research in many ways, including direct funding of some critical R&D areas for diagnostics, vaccines, and therapeutics that could strengthen biodefense preparedness. This three-part webinar details for the biotechnology corporate and academic community the many new and previously available sources of capital, as well as the processes for applying for funding, from the US Department of Defense.

The Department of Defense (DoD) is continuously engaging in efforts to protect the warfighter from a broad array of threats. Preparing for and responding to these threats requires key partnerships with the industry to develop vaccines, therapeutics, and diagnostics that are designed specifically to meet the unique needs of the warfighter in various situations. Many of the investments made through these partnerships also support broader applications of key biotechnologies for other unmet healthcare needs. This important webinar represents an opportunity for BIO members and the whole biotechnology community to get an update about the priorities and programs within the DoD and the ways companies can work with the Agency on their priorities.

Part 1—Opening Remarks on DoD Priorities and Investing at the Speed of Need: Novel Technologies and Platforms to Accelerate Drug Development (60 minutes)

Part 2—Repurposing and Redirecting: An Alternate Approach to Accelerating Medical Countermeasures (42 minutes)

Part 3—How to Work with DoD (16 minutes)

DoD Webinar part 1 Screenshot
Part 1 of 3—Investing at the Speed of Need: Novel Technologies and Platforms to Accelerate Drug Development
DoD Webinar part 2 Screenshot
Part 2 of 3—Repurposing and Redirecting: An Alternate Approach to Accelerating Medical Countermeasures
DoD Webinar part 3 Screenshot
Part 3 of 3—How to Work with DoD
Coronavirus
Biotech Response to COVID-19

As the threat of the novel coronavirus continues to grow globally, innovative biopharmaceutical companies are ramping up efforts to study the virus and develop vaccines and cures to protect individuals from contracting the virus.

Blog Posts
Covid Vaccine
March 11, 2022
Two years ago, the World Health Organization (WHO) declared COVID-19 a “pandemic.” We look back at key activities from BIO and the biopharmaceutical industry—and where we go from here.
Support Ukraine
March 8, 2022
Adding to the wide-scale human suffering across Ukraine, Russia’s unprovoked invasion of Ukraine is causing a major disruption to both medical as well as agricultural supply chains in the region and worldwide. As…
heart disease
February 24, 2022
Heart disease is the leading cause of death in America. During American Heart Month, we explore how to improve cardiovascular disease outcomes. “Heart disease costs our healthcare system $216 billion dollars annually,…
Press Releases
June 14, 2022
The Biotechnology Innovation Organization (BIO) is pleased to announce the election of its new Executive Committee directors for the 2022-2023 term. BIO’s Board elections took place Monday, June 13 during the 2022 BIO International Convention hosted by BIO in San Diego, June 13-16, 2022. “On…
June 13, 2022
The third annual report that examines diversity, equity, and inclusion (DEI) in the biotechnology industry launched today at the 2022 BIO International Convention. The report, “Measuring Diversity in the Biotech Industry: Tracking Progress in Small and Large Companies”, investigates the state of…
June 14, 2022
The licensing of university and nonprofit research has made a significant contribution to US gross domestic product (GDP), industrial gross output, and jobs over the last 25 years and underscores the importance of basic and applied research to the US economy, as well as the demand for public…
Letters, Comments & Testimony
August 2, 2022
On behalf of the Biotechnology Innovation Organization, I want to thank you for introducing the Patent Eligibility Restoration Act. This important legislation will bring much-needed and overdue clarity to Section 101 of the Patent Act. The existing uncertainty in the law has been a major impediment…
July 29, 2022
The Council of State Bioscience Associations (CSBA) is an alliance of independent, state and territory based, non-profit trade associations, each of which advocates for public policies that support responsible development and delivery of innovative life-enhancing and life-saving biotechnology…
June 12, 2022
On Monday, June 13th, BIO submitted comments in response to a recently published FDA draft guidance providing recommendations to sponsors on developing a Race and Ethnicity Diversity Plan to enroll adequate numbers of participants in clinical trials from underrepresented racial and ethnic…
Join BIOAction
Become an Advocate for Biotechnology

Sign-up to join BIOAction, BIO's grassroots advocacy program. You will be notified about relevant policy issues where we need you to contact your lawmaker.